IDEXX Laboratories Announces Fourth Quarter and Full Year 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
IDEXX Labs (IDXX) Tops Q4 EPS by 14c, Revenues Beat; Raises FY20 EPS/Revenue Guidance
January 31, 2020 6:35 AM ESTIDEXX Labs (NASDAQ: IDXX) reported Q4 EPS of $1.04, $0.14 better than the analyst estimate of $0.90. Revenue for the quarter came in at $605 million versus the consensus estimate of $600.56 million.
Achieves revenue growth in Q4 of 10% on a reported and organic basis, driven by CAG Diagnostics recurring revenue reported and organic growth of 11%Reports 19% year-over-year increase in Catalyst placements at new and competitive accounts in Q4, supporting full year growth of 16% in IDEXX\'s premium instrument installed baseDelivers full year EPS of $4.89, representing 15% growth on a reported basis and 21% on a comparable constant currency... More